Jacob Discusses Bladder Preservation as Top Refusal Reason in SunRISe-1

Joseph M. Jacob, MD, urological oncologist, Department of Urology, Upstate Medical University, Syracuse, New York, discusses the key takeaways from the SunRISe-1 study (NCT04640623) and data presented at the 2024 Genitourinary Cancers Symposium.

.

Preliminary results from the study focused on reasons for refusal of or ineligibility for radical cystectomy among patients with Bacillus Calmette–Guérin-unresponsive high-risk non-muscle-invasive bladder cancer who were enrolled in the TAR-200 monotherapy cohort of the SunRISe-1 study.

A total of 52 patients were treated and overall, 51 (94%) refused radical cystectomy. The most common reason for refusal was a preference for bladder preservation (52%). This was followed by concern about quality-of-life (37%).

Jacob concludes by discussing what the next steps for this research entail.

Transcription:

0:09 | For this particular poster, the big takeaway would be that patients [who are] healthy and who would otherwise be fit for cystectomy are really choosing to try to seek out salvage approaches mainly for bladder preservation reasons and for quality-of-life reasons. I think that there is a strong need, a strong desire from patients for these treatments to be available and for us to develop these effective treatments.

0:49 | Luckily, and so fortunately, what we are seeing so far is the results are excellent, much better than we thought they were going to be. Almost 80% of patients are having a complete response at this point. This is preliminary data, but so far, most patients are successfully preserving their bladder.

1:12 | Of course, we have to see how [the data] plays out. We still need to gather more time, more data points. So far, we are dealing with a small group of patients right now. The study has accrued very well and it's almost done accruing, so we'll have that data soon. Then we just have to wait and just make sure, [which] I think is just as important as complete response rate. We want to know that this is also a durable treatment, meaning that when they respond, they tend to respond for a long period of time. We want to know, how are these patients doing at 1 year, at 18 months, at 24 months, and so that's the next step, it is to show patients that this not only is an effective treatment, but it can be a long-term solution as well.